TEL AVIV, Israel, May 12, 2011 /PRNewswire/ — InspireMD, Inc.
(OTC BB: NSPR) (“Inspire” or the “Company”), the developer of the
MGuard™ mesh protective stent system, is
happy to announce that MGuard is now available in India. MGuard,
InspireMD’s flagship product is India’s first mesh-based coronary
stent system and received a very warm welcome by the local
cardiology community.
InspireMD will distribute the MGuard stent through KTPL, one of
the leading suppliers of high-tech medical equipment in India. KTPL
has already closed an initial order for the MGuard stent in India.
“Indians have one of the highest mortality and morbidity rates
from Coronary artery disease (CAD) as compared to other ethnic
groups and we are confident that the MGuard mesh-based
coronary stent system will become a very valuable new tool in
the Indian cath labs, in which AMI patients are the vast majority,”
stated Asher Holzer, PhD President of InspireMD. “For the
past two years, MGuard has met with much success in Europe and in
South America. India possesses highly qualified
interventional cardiologists and well-equipped hospitals, and I
have full confidence that the country’s cardiologists will welcome
this new solution to distal embolization, one of the most common
side effects in PCI procedures during AMI. We are also very
glad to be teaming up with Kirloskar Technologies, a most capable
partner and distributor of well known international manufacturers
of high tech medical equipment in India. The initial order
demonstrates the viability of this market and Kirloskar’s
commitment to making the MGuard a success in India.”
Prof. Yaron Almagor from the Jesselson Heart Center, Shaare
Zedek Medical Center, Jerusalem, was recently invited to India to
present the MGuard technology.
“We have had good experience with MGuard in preventing
dista
‘/>”/>
